By Christine Chen and Rishav Chatterjee SYDNEY (Reuters) -Australian biotech CSL has cut its profit outlook and delayed plans to spin off its vaccine division, blaming an unprecedented fall in U.S. flu immunisation rates, which knocked its shares down as much as 16.6% to a near seven-year low. At CSL’s annual meeting in Melbourne on Tuesday, investors frustrated with the former market darling's tanking share price also rejected executive pay packages for the second year in a row, but the board survived a spill motion. CSL, Australia's fourth-largest company by market value, told shareholders in August it would spin off its Seqirus vaccines unit and list it on the Australian Securities Exchange by June next year as part of a broader restructure that also involved cutting 3,000 jobs. The dem

See Full Page